Magnetoencephalography / Magnetic Resonance Spectroscopy Dose Response Study of Arbaclofen in Autism Spectrum Disorder
Phase of Trial: Phase 0
Latest Information Update: 06 Jan 2017
At a glance
- Drugs Arbaclofen (Primary)
- Indications Autistic disorder; Pervasive child development disorders
- Focus Therapeutic Use
- 03 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 03 Jan 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017.
- 04 Mar 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.